198 related articles for article (PubMed ID: 17234160)
1. Differences in the cellular response and signaling pathways of cisplatin and BBR3464 ([[trans-PtCl(NH3)(2)]2mu-(trans-Pt(NH3)(2)(H2N(CH2)(6)-NH2)2)]4+) influenced by copper homeostasis.
Kabolizadeh P; Ryan J; Farrell N
Biochem Pharmacol; 2007 May; 73(9):1270-9. PubMed ID: 17234160
[TBL] [Abstract][Full Text] [Related]
2. Biological consequences of trinuclear platinum complexes: comparison of [[trans-PtCl(NH3)2]2mu-(trans-Pt(NH3)2(H2N(CH2)6-NH2)2)]4+ (BBR 3464) with its noncovalent congeners.
Harris AL; Ryan JJ; Farrell N
Mol Pharmacol; 2006 Feb; 69(2):666-72. PubMed ID: 16275707
[TBL] [Abstract][Full Text] [Related]
3. Comparison of cytotoxicity and cellular accumulation of polynuclear platinum complexes in L1210 murine leukemia cell lines.
Roberts JD; Peroutka J; Beggiolin G; Manzotti C; Piazzoni L; Farrell N
J Inorg Biochem; 1999 Oct; 77(1-2):47-50. PubMed ID: 10626353
[TBL] [Abstract][Full Text] [Related]
4. Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper.
Katano K; Kondo A; Safaei R; Holzer A; Samimi G; Mishima M; Kuo YM; Rochdi M; Howell SB
Cancer Res; 2002 Nov; 62(22):6559-65. PubMed ID: 12438251
[TBL] [Abstract][Full Text] [Related]
5. Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters.
Samimi G; Howell SB
Cancer Chemother Pharmacol; 2006 Jun; 57(6):781-8. PubMed ID: 16170571
[TBL] [Abstract][Full Text] [Related]
6. Confocal microscopic analysis of the interaction between cisplatin and the copper transporter ATP7B in human ovarian carcinoma cells.
Katano K; Safaei R; Samimi G; Holzer A; Tomioka M; Goodman M; Howell SB
Clin Cancer Res; 2004 Jul; 10(13):4578-88. PubMed ID: 15240550
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of the membrane interaction of polynuclear platinum anticancer agents. Implications for cellular uptake.
Liu Q; Qu Y; Van Antwerpen R; Farrell N
Biochemistry; 2006 Apr; 45(13):4248-56. PubMed ID: 16566599
[TBL] [Abstract][Full Text] [Related]
8. Development of resistance to a trinuclear platinum complex in ovarian carcinoma cells.
Perego P; Gatti L; Righetti SC; Beretta GL; Carenini N; Corna E; Dal Bo L; Tinelli S; Colangelo D; Leone R; Apostoli P; Lombardi L; Beggiolin G; Piazzoni L; Zunino F
Int J Cancer; 2003 Jul; 105(5):617-24. PubMed ID: 12740909
[TBL] [Abstract][Full Text] [Related]
9. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells.
Samimi G; Safaei R; Katano K; Holzer AK; Rochdi M; Tomioka M; Goodman M; Howell SB
Clin Cancer Res; 2004 Jul; 10(14):4661-9. PubMed ID: 15269138
[TBL] [Abstract][Full Text] [Related]
10. Cellular pharmacology of polynuclear platinum anti-cancer agents.
Roberts JD; Peroutka J; Farrell N
J Inorg Biochem; 1999 Oct; 77(1-2):51-7. PubMed ID: 10626354
[TBL] [Abstract][Full Text] [Related]
11. Studies on synthesis, activity and binding with DNA of a new trinuclear platinum compound [{trans-PtCl(NH3)2}2{trans-Pt(thiazole)2}{H2N(CH2)(6NH2}2]Cl3(NO3).
Al-Shuneigat J; Qing Y; Beale P; Fisher K; Huq F
Med Chem; 2011 Jan; 7(1):1-8. PubMed ID: 21235513
[TBL] [Abstract][Full Text] [Related]
12. Platinum anticancer agents and antidepressants: desipramine enhances platinum-based cytotoxicity in human colon cancer cells.
Kabolizadeh P; Engelmann BJ; Pullen N; Stewart JK; Ryan JJ; Farrell NP
J Biol Inorg Chem; 2012 Jan; 17(1):123-32. PubMed ID: 21918844
[TBL] [Abstract][Full Text] [Related]
13. DNA modifications by a novel bifunctional trinuclear platinum phase I anticancer agent.
Brabec V; Kaspárková J; Vrána O; Nováková O; Cox JW; Qu Y; Farrell N
Biochemistry; 1999 May; 38(21):6781-90. PubMed ID: 10346899
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and activity of a trinuclear platinum complex: [{trans-PtCl(NH3)2}2mu-{trans-Pt(3-hydroxypyridine)2(H2N(CH2)6NH2)2}]Cl4 in ovarian cancer cell lines.
Tayyem H; Huq F; Yu JQ; Beale P; Fisher K
ChemMedChem; 2008 Jan; 3(1):145-51. PubMed ID: 17963210
[TBL] [Abstract][Full Text] [Related]
15. Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs.
Safaei R; Howell SB
Crit Rev Oncol Hematol; 2005 Jan; 53(1):13-23. PubMed ID: 15607932
[TBL] [Abstract][Full Text] [Related]
16. Cross-resistance to cisplatin in cells with acquired resistance to copper.
Safaei R; Katano K; Samimi G; Naerdemann W; Stevenson JL; Rochdi M; Howell SB
Cancer Chemother Pharmacol; 2004 Mar; 53(3):239-46. PubMed ID: 14648017
[TBL] [Abstract][Full Text] [Related]
17. Differential recognition by the tumor suppressor protein p53 of DNA modified by the novel antitumor trinuclear platinum drug BBR3464 and cisplatin.
Kasparkova J; Fojta M; Farrell N; Brabec V
Nucleic Acids Res; 2004; 32(18):5546-52. PubMed ID: 15486204
[TBL] [Abstract][Full Text] [Related]
18. Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B.
Samimi G; Katano K; Holzer AK; Safaei R; Howell SB
Mol Pharmacol; 2004 Jul; 66(1):25-32. PubMed ID: 15213293
[TBL] [Abstract][Full Text] [Related]
19. Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells.
Kalayda GV; Wagner CH; Buss I; Reedijk J; Jaehde U
BMC Cancer; 2008 Jun; 8():175. PubMed ID: 18565219
[TBL] [Abstract][Full Text] [Related]
20. Factors affecting sensitivity to antitumor platinum derivatives of human colorectal tumor cell lines.
Kitada N; Takara K; Minegaki T; Itoh C; Tsujimoto M; Sakaeda T; Yokoyama T
Cancer Chemother Pharmacol; 2008 Sep; 62(4):577-84. PubMed ID: 18030470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
